Abstracts Archive - Page 2344 of 2425 - ACR Meeting Abstracts

Abstract Number: 1160 • 2012 ACR/ARHP Annual Meeting
Assessment of Subclinical Synovitis by Power Doppler Ultrasonography in Patients with Juvenile Idiopathic Arthritis
Maria Teresa Terreri¹, Vanessa M. Bugni², Claudio A. Len², Sônia de A.V. Mitraud³, Rita NV. Furtado⁴ and Jamil Natour⁵, ¹Pediatrics, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, ²Pediatrics, Universidade Federal de São Paulo / UNIFESP, São Paulo, Brazil, ³Radiology and Diagnostic Imaging, Escola Paulista de Medicina/ Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, Brazil, ⁴Rheumatology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood, leading to physical disability and poor quality of life. Advances in…
Abstract Number: 1161 • 2012 ACR/ARHP Annual Meeting
Current Evidence of Anti-TNFα Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta-Analysis Approach Comparing the Different Drugs
Gabriele Simonini¹, Kate Druce², Rolando Cimaz¹, Gary J. Macfarlane² and Gareth T. Jones², ¹Pediatric Rheumatology, Anna Meyer Children's Hospital-University of Florence, Firenze, Italy, ²Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: To summarize evidence regarding the effectiveness of anti-TNFα treatments in childhood autoimmune chronic uveitis (ACU), non responder and/or failure to previous DMARD course.Methods: A…
Abstract Number: 1162 • 2012 ACR/ARHP Annual Meeting
Patients with Juvenile Idiopathic Arthritis From a Low Socio-Economic Background Perceive Their Disease Activity and Physical Limitations Higher Than Patients from a High Socio-Economic Background
Suzanne Verstappen¹, Joanna Cobb², H. E. Foster³, Eileen Baildam⁴, Lucy R. Wedderburn⁵, Janet Gardner-Medwin⁶, Alice Chieng⁷, Joyce Davidson⁶, Wendy Thomson⁸ and Kimme L. Hyrich⁹, ¹Arthritis Research UK Epidemiology Unit,, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ²Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Newcastle Hospitals NHS Foundation Trust and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁴Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁵Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ⁶Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁷Manchester Children's Hospital, Manchester, United Kingdom, ⁸Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, ⁹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: It has been suggested that socio-economic status (SES) may be associated with delayed to access to rheumatology care and with worse disease severity…
Abstract Number: 1163 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Radiologic Progression in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
Tomohiro Kubota¹, Tsuyoshi Yamatou², Yukiko Nonaka², Harumi Akaike², Tomokazu Nagakura³, Yuichi Yamasaki¹, Tomoko Takezaki², Yasuhito Nerome², Hiroyuki Imanaka² and Syuji Takei⁴, ¹Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ²Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ³Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, ⁴School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
Background/Purpose: Progression of joint damage is sometimes observed in JIA patients during the biologic therapy. However, it is difficult to evaluate the radiographic progression by…
Abstract Number: 1164 • 2012 ACR/ARHP Annual Meeting
Orofacial Anomalies in Children with Confirmed Juvenile Idiopathic Arthritis
Bernd Koos¹, Franka Stahl de Castrillon², Robert Ciesielski¹ and Nikolay Tzaribachev³, ¹Clinic of Orthodontics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany, ²Department of Orthodontics, University of Rostock, Germany, Department of Orthodontics, University of Rostock, Germany, Rostock, Germany, ³Pediatric Rheumatology, Center for Rheumatic Diseases, Bad Bramstedt, Germany
Background/Purpose: In children with juvenile idiopathic arthritis (JIA) temporomandibular joints (TMJ) are affected in up to 96% of the patients, where TMJ arthritis is frequently…
Abstract Number: 1165 • 2012 ACR/ARHP Annual Meeting
Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Nicoletta Solari¹, Elena Palmisani¹, Alessandro Consolaro¹, Sara Dalprà¹, Benedetta Schiappapietra¹, Giulia Bracciolini¹, Silvia Rosina¹, Giorgia Negro¹, Alberto Martini² and Angelo Ravelli³, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The advent of new therapies for juvenile idiopathic arthritis (JIA), particularly the introduction of biologic medications, has increased considerably the potential for treatment benefit,…
Abstract Number: 1166 • 2012 ACR/ARHP Annual Meeting
Clinical and Therapeutic Features of 312 Patients with Macrophage Activation Syndrome Enrolled in a Multinational Survey
Sergio Davì¹, Francesca Minoia¹, Erkan Demirkaya², Chiara Suffia³, Mario Abinun⁴, Amita Aggarwal⁵, Nuray Aktay Ayaz⁶, Maria Alessio⁷, Jordi Anton⁸, Maria Apaz⁶, Tadej Avcin⁹, Patrizia Barone¹⁰, Blanca E. Bica¹¹, Isabel Bolt¹², Luciana Breda¹³, Vyacheslav Chasnyk¹⁴, Rolando Cimaz⁶, Fabrizia Corona⁶, Ruben Cuttica¹⁵, Gianfranco D'Angelo¹⁶, AnnaCarin Horne¹⁷, Nicola Ruperto¹⁸, Alberto Martini¹⁹, Randy Q. Cron²⁰ and Angelo Ravelli⁶, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²International Investigator Consortium for MAS Diagnostic Criteria, Ankara, Turkey, ³Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genova, Italy, ⁴International Investigator Consortium for MAS Diagnostic Criteria, Newcastle upon Tyne, United Kingdom, ⁵Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁶Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ⁷Department of Pediatrics, Rheumatology Unit, University of Naples Federico II, Naples, Italy, ⁸Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, ⁹International Investigator Consortium for MAS Diagnostic Criteria, Ljubljana, Slovenia, ¹⁰Azienda Policlinico Università di Catania, Catania, Italy, ¹¹International Investigator Consortium for MAS Diagnostic Criteria, Rio de Janeiro, Brazil, ¹²Kinderspital Zuerich, Universitaetskinderklinik, Zurich, Switzerland, ¹³International Investigator Consortium for MAS Diagnostic Criteria, Chieti, Italy, ¹⁴Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, ¹⁵International Investigator Consortium for MAS Diagnostic Criteria, Buenos Aires, Argentina, ¹⁶International Investigator Consortium for MAS Diagnostic Criteria, Ancona, Italy, ¹⁷Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden, ¹⁸Istituto Gaslini, Genova, Italy, ¹⁹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ²⁰Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: A multinational collaborative effort aimed to develop a new set of criteria for macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA) has…
Abstract Number: 1167 • 2012 ACR/ARHP Annual Meeting
Golimumab in 25 Young Adults Affected by Juvenile Idiopathic ARTHRITIS NON Responders to OTHER Biological Agents: Preliminary DATA
Irene Pontikaki¹, Orazio De Lucia², Maurizio Gattinara³, Alessandra Salmaso¹, Pier Luigi Meroni⁴ and Valeria Gerloni¹, ¹Pediatric Rheumatology, Orthopedic Institute Gaetano Pini, Milano, Italy, ²Rheumatology, Orthopedic Institute Gaetano Pini, Milano, Italy, ³Pediatric Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁴Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy
Background/Purpose: Biological agents licensed in JIA have demonstrated a favourable benefit-to-risk profile. Nevertheless, intolerance, loss and lack of efficacy or adverse events have led to…
Abstract Number: 1168 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis of Early Biologic Treatment in Polyarticular Juvenile Idiopathic Arthritis
Nadia Luca¹, Heather Burnett², Wendy Ungar², Timothy Beukelman³, Brian M. Feldman⁴, Gwen Schwartz⁵ and Ahmed Bayoumi⁶, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ³Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Health Economics Unit, St. Michael's Hospital, Toronto, ON, Canada, ⁶General Internal Medicine, Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada
Background/Purpose: The optimal timing of high cost biologic therapies in the treatment of polyarticular juvenile idiopathic arthritis (JIA) is uncertain. We evaluated the economic and…
Abstract Number: 1169 • 2012 ACR/ARHP Annual Meeting
Obstetrical Complications in Women with Juvenile Idiopathic Arthritis
Evelyne Vinet¹, Sasha Bernatsky², Mohammed Kaouache², Christian A. Pineau³, Ann E. Clarke⁴, Elizabeth Hazel⁵, Ciaran M. Duffy⁶, Anick Bérard⁷ and Debbie Ehrmann Feldman⁸, ¹McGill University Health Center, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁵Rhematology, McGill University Health Centre, Montreal, QC, Canada, ⁶Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁷Université de Montréal, Montréal, QC, Canada, ⁸Rehabilitation, Université de Montréal, Montreal, QC, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) most often affects women before childbearing age. Patients with JIA and their parents often ask about the potential impact of…
Abstract Number: 1170 • 2012 ACR/ARHP Annual Meeting
Folate Usage in Methotrexate -Treated Juvenile Idiopathic Arthritis Patients Is Inconsistent and Highly Variable
Gil Amarilyo¹, Ornella J. Rullo², Deborah K. McCurdy³, Jennifer M.P. Woo¹ and Daniel Furst⁴, ¹Pediatrics/Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, ²Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁴David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA
Background/Purpose: Low-dose weekly methotrexate (MTX) is the first-choice second-line drug in the treatment of juvenile idiopathic arthritis (JIA). Folate (as either Folic acid (FA) or…
Abstract Number: 1171 • 2012 ACR/ARHP Annual Meeting
Validation of BASDAI and BASFI in Children with Spondyloarthritis
Alisa C. Rachlis¹, Bertha Wong², Kristi J. Whitney-Mahoney³, Michelle Batthish², Michelle Anderson⁴, JoAnne Marcuz⁴, Margaret Reaume⁴, Ashley DeLaurier⁵, Ronald Laxer⁴, Brian M. Feldman⁵ and Shirley M. Tse², ¹Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Pediatric Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Rehab Services, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile-onset Spondyloarthritis (JSpAs), referred to as Enthesitis-Related Arthritis (ERA) subtype under the International League of Associations for Rheumatology (ILAR) classification is characterized by arthritis…
Abstract Number: 1172 • 2012 ACR/ARHP Annual Meeting
Delineating the Role of Multiple Corticosteroid Joint Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era
Charalampia Papadopoulou¹, Maria I. Gonzalez¹, Juan C. Nieto¹, Mikhail Kostik², Marek Bohm¹, Stefano Lanni¹, Valentina Muratore³, Alessandro Consolaro¹, Alberto Martini⁴ and Angelo Ravelli⁵, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ³Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁴Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ⁵University of Genova, Genova, Italy
Background/Purpose: Intra-articular corticosteroid injection (IACI) therapy in juvenile idiopathic arthritis (JIA) is generally considered for the treatment of children with arthritis in a small number…
Abstract Number: 1173 • 2012 ACR/ARHP Annual Meeting
Targeting Remission in Juvenile Idiopathic Arthritis in Routine Clinical Care: Experience in 175 Newly-Diagnosed Patients
Alessandro Consolaro¹, Giorgia Negro¹, Nicoletta Solari¹, Cristina Ferrari¹, Sergio Davì¹, Silvia Pederzoli¹, Giulia Bracciolini¹, Maria C. Gallo¹, Alberto Martini² and Angelo Ravelli³, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The recent advances in the management of juvenile idiopathic arthritis (JIA) have increased considerably the potential to achieve disease remission or, at least, low…
Abstract Number: 1174 • 2012 ACR/ARHP Annual Meeting
Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study
Ricardo A. G. Russo¹ and Marìa M. Katsicas², ¹Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina
Background/Purpose: biologic agents have revolutionized the treatment of Juvenile Idiopathic Arthritis (JIA) and other conditions due to their high efficacy and safety. However, with the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].